Publications by authors named "Joth Jacobson"

Claim this Profile
P
Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.
Scott E Kasner, Lars Thomassen, Lars Søndergaard, John F Rhodes, Coby C Larsen, Joth Jacobson

Int J Stroke· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fracture of the GORE HELEX septal occluder: associated factors and clinical outcomes.
Thomas Fagan, Dennis Dreher, Warren Cutright, Joth Jacobson, Larry Latson

Catheter Cardiovasc Interv· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the U.S. multicenter pivotal study of the HELEX septal occluder for percutaneous closure of secundum atrial septal defects.
Thomas K Jones, Larry A Latson, Evan Zahn, Craig E Fleishman, Joth Jacobson

J Am Coll Cardiol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder.
Larry A Latson, Thomas K Jones, Joth Jacobson, Evan Zahn, John F Rhodes

Am Heart J· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in biology and therapy of multiple myeloma.
Sophie Barillé-Nion, Bart Barlogie, Régis Bataille, P Leif Bergsagel, Joshua Epstein, Joth Jacobson

Hematology Am Soc Hematol Educ Program· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Maurizio Zangari, Bart Barlogie, Elias Anaissie, Fariba Saghafifar, Paul Eddlemon, Joth Jacobson

Br J Haematol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.
Brian G M Durie, Joth Jacobson, Bart Barlogie, John Crowley

J Clin Oncol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of multiple myeloma.
Bart Barlogie, John Shaughnessy, Guido Tricot, Joth Jacobson, Maurizio Zangari

Blood· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
Joth Jacobson, Bart Barlogie, John Shaughnessy, Johannes Drach, Guido Tricot

Br J Haematol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
Joth L Jacobson, Mohamad A Hussein, Bart Barlogie, Brian G M Durie, John J Crowley

Br J Haematol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Choon-Kee Lee, Bart Barlogie, Nikhil Munshi, Maurizio Zangari, Athanasios Fassas, Joth Jacobson

J Clin Oncol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.
Kai-Da Wu, Lisa M Orme, John Shaughnessy, Joth Jacobson, Bart Barlogie

Blood· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Maurizio Zangari, Bart Barlogie, Raymond Thertulien, Joth Jacobson, Paul Eddleman

Clin Lymphoma· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
John Shaughnessy, Joth Jacobson, Jeff Sawyer, Jason McCoy, Athanasios Fassas

Blood· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
Madhav V Dhodapkar, Joth L Jacobson, Morie A Gertz, John J Crowley, Bart Barlogie

Semin Oncol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
John Shaughnessy, Erming Tian, Jeffrey Sawyer, Jason McCoy, Guido Tricot, Joth Jacobson

Br J Haematol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Choon Kee Lee, Ashraf Badros, Bart Barlogie, Christopher Morris, Maurizio Zangari, Joth Jacobson

Exp Hematol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study.
Cary A Presant, Joth Jacobson, Walter Wolf, Victor Waluch, Ilene C Weitz

Invest New Drugs· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partitioning and peeling for constructing prognostic groups.
Michael LeBlanc, Joth Jacobson, John Crowley

Stat Methods Med Res· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis